iX Biopharma Ltd. (SGX:42C)

iX Biopharma Ratios and Metrics

Market cap in millions SGD. Fiscal year is July - June.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 29, 2026	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Market Capitalization	399	14	22	70	122	167
Market Cap Growth	1865.24%	-36.24%	-68.05%	-43.05%	-26.84%	3.17%
Enterprise Value	400	17	22	62	111	162
PS Ratio	55.23	1.83	3.74	11.79	8.51	95.91
PB Ratio	96.58	38.92	5.13	4.40	6.20	14.29
P/TBV Ratio	102.99	149.55	5.51	4.48	6.31	14.81
P/FCF Ratio	-	-	-	-	41.89	-
P/OCF Ratio	-	-	-	-	39.21	-
EV/Sales Ratio	55.37	2.20	3.73	10.51	7.70	92.74
EV/EBITDA Ratio	-	-	-	-	96.40	-
EV/EBIT Ratio	-	-	-	-	221.09	-
EV/FCF Ratio	-104.99	-	-	-	37.89	-
Debt / Equity Ratio	1.63	16.17	1.20	0.27	0.22	0.36
Debt / EBITDA Ratio	-	-	-	-	2.91	-
Debt / FCF Ratio	-	-	-	-	1.51	-
Net Debt / Equity Ratio	0.23	13.61	0.77	-0.14	-0.46	-0.17
Net Debt / EBITDA Ratio	-0.18	-0.85	-0.47	0.24	-7.99	0.18
Net Debt / FCF Ratio	-0.25	-1.25	-0.49	0.26	-3.14	0.22
Asset Turnover	0.50	0.60	0.30	0.22	0.61	0.10
Inventory Turnover	5.46	4.98	4.21	3.86	2.09	2.14
Quick Ratio	0.91	0.32	0.65	1.34	1.98	2.19
Current Ratio	1.05	0.47	0.89	1.53	2.14	2.55
Return on Equity (ROE)	-155.52%	-431.07%	-106.91%	-54.02%	-29.23%	-75.27%
Return on Assets (ROA)	-24.84%	-30.32%	-23.69%	-22.32%	1.32%	-39.86%
Return on Capital Employed (ROCE)	-72.70%	-272.70%	-103.50%	-53.80%	2.40%	-75.20%
Earnings Yield	-1.49%	-71.38%	-48.44%	-13.79%	-3.75%	-4.92%
FCF Yield	-0.95%	-27.87%	-30.64%	-11.98%	2.39%	-5.32%
Buyback Yield / Dilution	-9.14%	-14.25%	-0.33%	-2.51%	-7.60%	-7.13%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.